secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regulus Therapeutics Inc. (—)
CIK:        0001505512
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-135281
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regulus Q1 net loss $8.5M; cash $107.7M; RGLS8429 cohort 4 dosed
----------------------------------------------------------------

- Net loss of $8.5M ($0.29/shr) vs $7.1M ($0.42/shr) in Q1 2023.
- Cash, equivalents & investments $107.7M at Mar 31, 2024; runway into H1 2026.
- Initiated 4th & final cohort of Phase 1b MAD trial for RGLS8429 in ADPKD; topline from cohort 3 expected mid-2024.
- Closed oversubscribed $100M private placement in Mar 2024 with new and existing institutional investors.
- R&D expense $6.0M (up 22% YoY); G&A expense $2.8M (up 17% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1505512/000119312524135281/0001193125-24-135281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1505512/000119312524135281/d791133d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-135281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer